Kala Pharmaceuticals Competitors

Kala Pharmaceuticals (NASDAQ:KALA) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

Analyst Ratings

This is a summary of current recommendations and price targets for Kala Pharmaceuticals and FibroGen, as reported by MarketBeat.com.

Kala Pharmaceuticals currently has a consensus target price of $21.8333, indicating a potential upside of 192.28%. FibroGen has a consensus target price of $45.8333, indicating a potential upside of 130.20%. Given Kala Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Kala Pharmaceuticals is more favorable than FibroGen.

Earnings and Valuation

This table compares Kala Pharmaceuticals and FibroGen's revenue, earnings per share and valuation.

FibroGen has higher revenue and earnings than Kala Pharmaceuticals. FibroGen is trading at a lower price-to-earnings ratio than Kala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

67.6% of Kala Pharmaceuticals shares are held by institutional investors. Comparatively, 75.1% of FibroGen shares are held by institutional investors. 34.2% of Kala Pharmaceuticals shares are held by company insiders. Comparatively, 3.4% of FibroGen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Kala Pharmaceuticals and FibroGen's net margins, return on equity and return on assets.

Risk and Volatility

Kala Pharmaceuticals has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500. Comparatively, FibroGen has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500.

Summary

FibroGen beats Kala Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Kala Pharmaceuticals (NASDAQ:KALA) and Morphic (NASDAQ:MORF) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, dividends and analyst recommendations.

Institutional & Insider Ownership

67.6% of Kala Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.5% of Morphic shares are owned by institutional investors. 34.2% of Kala Pharmaceuticals shares are owned by company insiders. Comparatively, 39.5% of Morphic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Kala Pharmaceuticals has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500. Comparatively, Morphic has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Kala Pharmaceuticals and Morphic, as provided by MarketBeat.com.

Kala Pharmaceuticals presently has a consensus price target of $21.8333, indicating a potential upside of 192.28%. Morphic has a consensus price target of $63.3333, indicating a potential upside of 14.98%. Given Kala Pharmaceuticals' higher possible upside, research analysts plainly believe Kala Pharmaceuticals is more favorable than Morphic.

Profitability

This table compares Kala Pharmaceuticals and Morphic's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Kala Pharmaceuticals and Morphic's revenue, earnings per share (EPS) and valuation.

Morphic has higher revenue and earnings than Kala Pharmaceuticals. Morphic is trading at a lower price-to-earnings ratio than Kala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Morphic beats Kala Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Pandion Therapeutics (NASDAQ:PAND) and Kala Pharmaceuticals (NASDAQ:KALA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.

Insider & Institutional Ownership

35.7% of Pandion Therapeutics shares are held by institutional investors. Comparatively, 67.6% of Kala Pharmaceuticals shares are held by institutional investors. 34.2% of Kala Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for Pandion Therapeutics and Kala Pharmaceuticals, as reported by MarketBeat.

Pandion Therapeutics currently has a consensus price target of $44.25, suggesting a potential downside of 26.31%. Kala Pharmaceuticals has a consensus price target of $21.8333, suggesting a potential upside of 192.28%. Given Kala Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Kala Pharmaceuticals is more favorable than Pandion Therapeutics.

Profitability

This table compares Pandion Therapeutics and Kala Pharmaceuticals' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Pandion Therapeutics and Kala Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Pandion Therapeutics has higher earnings, but lower revenue than Kala Pharmaceuticals.

Summary

Kala Pharmaceuticals beats Pandion Therapeutics on 6 of the 11 factors compared between the two stocks.

Five Prime Therapeutics (NASDAQ:FPRX) and Kala Pharmaceuticals (NASDAQ:KALA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Valuation and Earnings

This table compares Five Prime Therapeutics and Kala Pharmaceuticals' gross revenue, earnings per share and valuation.

Kala Pharmaceuticals has lower revenue, but higher earnings than Five Prime Therapeutics. Five Prime Therapeutics is trading at a lower price-to-earnings ratio than Kala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Five Prime Therapeutics and Kala Pharmaceuticals' net margins, return on equity and return on assets.

Volatility & Risk

Five Prime Therapeutics has a beta of 4.4, indicating that its stock price is 340% more volatile than the S&P 500. Comparatively, Kala Pharmaceuticals has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500.

Institutional & Insider Ownership

67.3% of Five Prime Therapeutics shares are owned by institutional investors. Comparatively, 67.6% of Kala Pharmaceuticals shares are owned by institutional investors. 6.4% of Five Prime Therapeutics shares are owned by company insiders. Comparatively, 34.2% of Kala Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and target prices for Five Prime Therapeutics and Kala Pharmaceuticals, as provided by MarketBeat.com.

Five Prime Therapeutics presently has a consensus price target of $30.7143, indicating a potential downside of 19.17%. Kala Pharmaceuticals has a consensus price target of $21.8333, indicating a potential upside of 192.28%. Given Kala Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Kala Pharmaceuticals is more favorable than Five Prime Therapeutics.

Summary

Kala Pharmaceuticals beats Five Prime Therapeutics on 9 of the 14 factors compared between the two stocks.

Cytokinetics (NASDAQ:CYTK) and Kala Pharmaceuticals (NASDAQ:KALA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, valuation and profitability.

Valuation and Earnings

This table compares Cytokinetics and Kala Pharmaceuticals' gross revenue, earnings per share and valuation.

Kala Pharmaceuticals has lower revenue, but higher earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Kala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

97.1% of Cytokinetics shares are owned by institutional investors. Comparatively, 67.6% of Kala Pharmaceuticals shares are owned by institutional investors. 6.4% of Cytokinetics shares are owned by insiders. Comparatively, 34.2% of Kala Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Cytokinetics and Kala Pharmaceuticals' net margins, return on equity and return on assets.

Risk & Volatility

Cytokinetics has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, Kala Pharmaceuticals has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Cytokinetics and Kala Pharmaceuticals, as reported by MarketBeat.com.

Cytokinetics currently has a consensus target price of $33.6364, indicating a potential upside of 36.18%. Kala Pharmaceuticals has a consensus target price of $21.8333, indicating a potential upside of 192.28%. Given Kala Pharmaceuticals' higher possible upside, analysts clearly believe Kala Pharmaceuticals is more favorable than Cytokinetics.

Summary

Cytokinetics beats Kala Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Kala Pharmaceuticals (NASDAQ:KALA) and Amneal Pharmaceuticals (NYSE:AMRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.

Insider and Institutional Ownership

67.6% of Kala Pharmaceuticals shares are held by institutional investors. Comparatively, 33.5% of Amneal Pharmaceuticals shares are held by institutional investors. 34.2% of Kala Pharmaceuticals shares are held by company insiders. Comparatively, 26.3% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Kala Pharmaceuticals and Amneal Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Kala Pharmaceuticals has higher earnings, but lower revenue than Amneal Pharmaceuticals. Kala Pharmaceuticals is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for Kala Pharmaceuticals and Amneal Pharmaceuticals, as provided by MarketBeat.com.

Kala Pharmaceuticals currently has a consensus price target of $21.8333, indicating a potential upside of 192.28%. Amneal Pharmaceuticals has a consensus price target of $7.00, indicating a potential upside of 18.85%. Given Kala Pharmaceuticals' higher possible upside, equities analysts clearly believe Kala Pharmaceuticals is more favorable than Amneal Pharmaceuticals.

Risk & Volatility

Kala Pharmaceuticals has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.

Profitability

This table compares Kala Pharmaceuticals and Amneal Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Amneal Pharmaceuticals beats Kala Pharmaceuticals on 7 of the 12 factors compared between the two stocks.